Peptide Tracker
← Library

3-residue chain

Cartalax (AED)

Khavinson cartilage bioregulator tripeptide (Ala-Glu-Asp)

10MG
Dose
20U
Draw
10D
Cycle

Cartalax is the tripeptide Ala-Glu-Asp from the Khavinson bioregulator family. No label, trial registry entry or human dosing study was found. Everything below is community practice from one non-primary page.

PTSEALEDCartalax20 MGLYOPHILIZED
Sign in to start this protocolSign in to mix a vial

Protocols

  • Community 10-day cyclerecommended

    Community practice, not from a label or trial: the shortest cycle in the 10-20 day community range.

Dosing

  • Community practice, not from a label or trial: 10 mg subcutaneous daily for a 10-20 day cycle, repeated every 3-6 months. The page says this comes from research literature and community protocols; it also lists a 20 mg variant and oral capsules without explaining how they fit.
  • No validated human dose exists.

Route & timing

Route: Subcutaneous (abdomen or thigh) per the community page; oral capsules also exist.

Timing: No reliable figure found in the sources; ask your prescriber or supplier.

Reconstitution

  • No sourced volume. The water in the protocol is arithmetic for a readable draw (20 mg vial + 0.4 mL gives 10 mg = 20 units), not a sourced instruction.

Reconstitution calculator

Concentration
50 mg/mL
Per unit
0.5 mg
Draw
20 units
Volume
0.2 mL
Doses per vial
2
Vials for cycle (10 doses), pooled
5
Vials, discard remainder
5
concentration = 20 / 0.4 = 50 mg/mL
per unit = 50 / 100 = 0.5 mg
units = 10 / 0.5 = 20
mL = 20 / 100 = 0.2
doses per vial = 20 / 10 = 2
pooled vials = ceil(10 x 10 / 20) = 5
discard vials = ceil(10 / floor(2)) = 5

Stability

No reliable figure found in the sources; ask your prescriber or supplier.

Off-cycle

3-6 months between 10-20 day cycles (community).

Why:

  • Community pattern; no trial supports the interval.

Stacking rules

  • Never draw into the same syringe as another compound; use separate syringes and distinct injection sites.

Safety

Unapproved research peptide; no regulatory approval found. No human safety studies were identified, so the absence of reported harms does not establish safety.

Common side effects:

  • Community page reports mild, uncommon injection-site reactions (its own claim, not independently sourced).

Stop and call your prescriber if:

  • Injection-site infection or spreading redness
  • Allergic reaction (rash, swelling, trouble breathing)

Markers to track

No reliable source names a biomarker for this compound.

Sources

Cartalax (AED)